Terapia indolore e non invasiva
per il cancro della pelle

Rhenium-SCT®

Bringing back Quality of Life

Non invasiva
Indolore
Unica seduta

Hai bisogno di un appuntamento?

E' stata cambiata o posticipata la data del tuo trattamento per il cancro della pelle a causa del COVID-19?

Con il Programma di riferimento Rhenium-SCT vi mettiamo in contatto diretto con il centro di trattamento più vicino.

Programma di riferimento Rhenium-SCT:

richiedi qui la prossima data disponibile per il trattamento.

Rhenium-SCT®

Non invasiva
Indolore
Estetica

La Rhenium-SCT (Skin Cancer Therapy) è una brachiterapia specializzata d’avanguardia che utilizza il radioisotopo Rhenium-188, un beta-emettitore che in questo caso viene utilizzato per il trattamento dei carcinomi basali e squamosi della pelle.

188W/188Re Generatori

produzione di 188Re ad alta emissione di energia.

Varie dimensioni disponibili

fino a 150GBq (4Ci) (4Ci) 188W

Alta concentrazione di attività

fino a 9GBq/ml

Volume di eluizione variabile

Volume di eluizione di 5-14 ml (eluizione parziale per piccoli volumi)

Bassa penetrazione

188W < 0.01 % rispetto a 188Re al momento della calibrazione

Chi siamo

OncoBeta GmbH è un pioniere nel settore dei radioisotopi, che attualmente offre una terapia innovativa per la cura del cancro della pelle che si rivolge ai tumori della pelle non melanoma e produce generatori di Tungsteno (Wolfram)-188/Renio-188 (W/Re-188) per uso commerciale.

Recent Events

COVID-19: We are here for you.

COVID-19: We are here for you.

To our Valued Patients, Customers and Health Care providers, As we navigate through these trying times surrounding the Coronavirus (COVID-19)...
Read More
B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.

B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.

New Delhi, India and Garching near Munich, Germany, 6th March, 2020. B.J Madan & Co and OncoBeta announced the execution...
Read More
RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.

Houston, TX, USA and OncoBeta GmbH, Garching/, Germany, February 7th, 2020 RadioMedix and OncoBeta today announced the execution of an...
Read More
Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

OncoBeta- A Pioneer And Innovator In The Epidermal Radioisotope Therapy Sector Skin is the largest organ of the body and...
Read More
First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

– The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau October 4, 2019;...
Read More
OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. July 5, 2019;...
Read More
Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

May 13 2019, Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope...
Read More
OncoBeta ® GmbH Named Among ‘30 Ethical Companies of the Year 2019’ by The Silicon Review Magazine

OncoBeta ® GmbH Named Among ‘30 Ethical Companies of the Year 2019’ by The Silicon Review Magazine

Recognition for OncoBeta`s mission to give non-melanocytic skin cancer patients back their quality of life. April 05, 2019; Garching near...
Read More
OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner

OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner

Recognition of OncoBeta’s success in developing and providing an innovative therapy for patients suffering from non-melanocytic skin cancer Feb 20,...
Read More
OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

Garching n. Munich, Germany, (January 10, 2019) – OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal...
Read More